NCT03594123View on ClinicalTrials.gov

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

PHASE3CompletedINTERVENTIONAL

Enrollment

259

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions

Alzheimer's Disease

Interventions

DRUG

Brexpiprazole

2 or 3 mg tablet

DRUG

Brexpiprazole

0.5 to 3 mg tablet

Trial Locations (1)

33155

For additional information regarding sites, contact 844-687-8522, Miami

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03594123 - A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type | Biotech Hunter | Biotech Hunter